Application of biomarkers in clinical development of biologics and bioanalytical strategies

doi:10.12092/j.issn.1009-2501.2020.01.004

Abstract

Abstract: China's biologic drug research and development is on a fast track lane. The rising cost of new drug development has not improved the success rate of drug launch, and a shift in the model of drug development is urgently needed. In order to improve the success rate, a biomarker strategy of the new drug development model has been proposed and is generally accepted. This paper reviews the research and development of new translational medicine drugs with biomarkers as the core, the application of biomarkers in the clinical study of biological drugs, biomarker biological analysis strategies, and the opportunities and challenges of biomarkers in the clinical study of biological drugs. By comparing international standards, seeking China's advantages and seeking opportunities from the research and development model of translational medicine based on biomarkers, China can make innovative drugs with global influence in the near term.

Key words: biological drugs, biomarkers, clinical research, translational medicine, bioanalysis

CLC Number:

R915

CHE Jinjing. Application of biomarkers in clinical development of biologics and bioanalytical strategies[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(1): 22-31.

References

［1］Thomas DW,Burns J,Audette J,et al.Clinical development success rates 2006-2015［J］. San Diego: Biomedtracker/Washington, DC: BIO/Bend: Amplion, 2016.
［2］Dimasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: New estimates of R&D costs［J］. J Health Econ, 2016, 47: 20-33.
［3］Dimasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs［J］. J Health Econ, 2003, 22(2): 151-185.
［4］Townsend MJ, Arron JR. Reducing the risk of failure: biomarker-guided trial design［J］. Nat Rev Drug Discov, 2016, 15(8): 517-518.
［5］Cook D, Brown D, Alexander R, et al. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework［J］. Nat Rev Drug Discov, 2014, 13(6): 419-431.
［6］Lalonde RL, Kowalski KG, Hutmacher MM, et al. Model-based drug development［J］. Clin Pharmacol Ther, 2007, 82(1): 21-32.
［7］Milligan PA, Brown MJ, Marchant B, et al. Model-based drug development: a rational approach to efficiently accelerate drug development［J］. Clin Pharmacol Ther, 2013, 93(6): 502-514.
［8］Dolgos H, Trusheim M, Gross D, et al. Translational medicine guide transforms drug development processes: the recent Merck experience［J］. Drug Discov Today, 2016, 21(3): 517-526.
［9］Subramanyam M, Goyal J. Translational biomarkers: from discovery and development to clinical practice［J］. Drug Discov Today Technol, 2016, 21-22: 3-10.
［10］Hurko O, Jones GK. Valuation of biomarkers［J］. Nat Rev Drug Discov, 2011, 10(4): 253-254.
［11］Parchment RE, Ferry-Galow KV, Doroshow JH. Integrating biomarkers in early-phase trials［M］. Kummar S, Takimoto C, editor, Novel designs of early phase trials for cancer therapeutics: Academic Press, 2018: 95-114.
［12］Parchment RE, Doroshow JH. Pharmacodynamic endpoints as clinical trial objectives to answer important questions in oncology drug development［J］. Semin Oncol, 2016, 43(4): 514-525.
［13］Morgan P, Van Der Graaf PH, Arrowsmith J, et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival［J］. Drug Discov Today, 2012, 17(9/10): 419-424.
［14］Normanno N, De Luca A, Maiello MR, et al. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in breast cancer: current status and future development ［J］. Front Biosci, 2005, 1(10): 2611-2617.
［15］Dancey JE, Dobbin KK, Groshen S, et al. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents［J］. Clin Cancer Res, 2010, 16(6): 1745-1755.
［16］Cox GF. The art and science of choosing efficacy endpoints for rare disease clinical trials［J］. Am J Med Genet A, 2018, 176(4): 759-772.
［17］史军. 夯实早期临床研发贯通中国R&D的价值链［R］. 北京大学临床研究所"国际创新药物研发和管理高级课程(CCDRS)", 2019-7.
［18］Chen C. Opportunities and pitfalls in clinical proof-of-concept: principles and examples［J］. Drug Discov Today, 2018, 23(4): 776-787.
［19］Lowe PJ, Hijazi Y, Luttringer O, et al. On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development［J］. Xenobiotica, 2007, 37(10/11): 1331-1354.
［20］Mclaughlin J, Han G, Schalper KA, et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer［J］. JAMA Oncol, 2016, 2(1): 46-54.
［21］Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility［J］. Nat Biotechnol, 2006, 24(8): 971-983.
［22］Goodsaid F, Frueh F. Biomarker qualification pilot process at the US food and drug administration［J］. Aaps J, 2007, 9(1): E105-E108.
［23］Subramanyam M, Goyal J. Translational biomarkers: from discovery and development to clinical practice［J］. Drug Discov Today Technol, 2016, 21: 3-10.
［24］Lee JW, Devanarayan V, Barrett YC, et al. Fit-for-purpose method development and validation for successful biomarker measurement［J］. Pharm Res, 2006, 23(2): 312-328.
［25］Chau CH, Rixe O, Mcleod H, et al. Validation of analytic methods for biomarkers used in drug development［J］. Clin Cancer Res, 2008, 14(19): 5967-5976.
［26］Meibohm B, Derendorf H. Pharmacokinetic/pharmacodynamic studies in drug product development［J］. J Pharm Sci, 2002, 91(1): 18-31.
［27］Muller PY, Brennan FR. Safety Assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies［J］. Clin Pharmacol Ther, 2009, 85(3): 247-258.
［28］Green CL, Stewart JJ, Hogerkorp CM, et al. Recommendations for the development and validation of flow cytometry-based receptor occupancy assays［J］. Cytometry B Clin Cytom, 2016, 90(2): 141-149.
［29］Pan WJ, Kock K, Rees WA, et al. Clinical pharmacology of AMG 181, a gut-specific human anti-alpha4beta7 monoclonal antibody, for treating inflammatory bowel diseases［J］. Br J Clin Pharmacol, 2014, 78(6): 1315-1333.
［30］Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates［J］. J Clin Oncol, 2010, 28(19): 3167-3175.
［31］Reilly M, Miller RM, Thomson MH, et al. Randomized, double-blind, placebo-controlled, dose-escalating phase I, healthy subjects study of intravenous OPN-305, a humanized anti-TLR2 antibody［J］. Clin Pharmacol Ther, 2013, 94(5): 593-600.
［32］Lebre MC, Vergunst CE, Choi IY, et al. Why CCR2 and CCR5 blockade failed and why CCR1 blockade might still be effective in the treatment of rheumatoid arthritis［J］. PLoS One, 2011, 6(7): e21772.
［33］Shi JG, Chen X, Lee F, et al. The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers［J］. J Clin Pharmacol, 2014, 54(12): 1354-1361.
［34］Liang M, Schwickart M, Schneider AK, et al. Receptor occupancy assessment by flow cytometry as a pharmacodynamic biomarker in biopharmaceutical development［J］. Cytometry Part B-Clinical Cytometry, 2016, 90(2): 117-127.
［35］Schwickart M, Chavez C, Henderson S, et al. Evaluation of assay interference and interpretation of CXCR4 receptor occupancy results in a preclinical study with MEDI3185, a fully human antibody to CXCR4［J］. Cytometry Part B-Clinical Cytometry, 2016, 90(2): 209-219.
［36］Vey N, Bourhis JH, Boissel N, et al. A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission［J］. Blood, 2012, 120(22): 4317-4323.
［37］Canonico B, Betti M, Luchetti F, et al. Flow cytometric profiles, biomolecular and morphological aspects of transfixed leukocytes and red cells［J］. Cytometry B Clin Cytom, 2010, 78(4): 267-278.
［38］Davis BH, Wood B, Oldaker T, et al. Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS-part I-rationale and aims［J］. Cytometry B Clin Cytom, 2013, 84(5): 282-285.
［39］Davis BH, Dasgupta A, Kussick S, et al. Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS-part II-preanalytical issues［J］. Cytometry B Clin Cytom, 2013, 84(5): 286-290.
［40］Tangri S, Vall H, Kaplan D, et al. Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS-part III-analytical issues［J］. Cytometry B Clin Cytom, 2013, 84(5): 291-308.
［41］Barnett D, Louzao R, Gambell P, et al. Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS-part IV-postanalytic considerations［J］. Cytometry B Clin Cytom, 2013, 84(5): 309-314.
［42］Wood B, Jevremovic D, Bene MC, et al. Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS-part V-assay performance criteria［J］. Cytometry B Clin Cytom, 2013, 84(5): 315-323.
［43］Fu J, Wang F, Dong LH, et al. Receptor occupancy measurement of anti-PD-1 antibody drugs in support of clinical trials［J］. Bioanalysis, 2019, 11(14): 1347-1358.

[1]	HE Lihua, ZHU Xiuzhi, JIANG Yizhou. Research progress on immunotherapy for triple-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 842-853.
[2]	FU Xiaoyu, KONG Deguang, LI Juanjuan. Treatment progress of triple positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 866-875.
[3]	ZHONG Wei, SHI Shuxia, QIN Qinyue, YU Guo. Measurement tools and rationality evaluation of clinical research coordinator's work ability and workload [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 937-947.
[4]	DING Hao, GAO Zhenhua, ZHENG Yun. Research progress of microRNA in diagnosis and treatment of prostate cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 696-708.
[5]	ZHOU Guangchen, LIU Yixi, ZHENG Yun. Colorectal cancer and microRNA: research progress [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 575-587.
[6]	CHE Jinjing, LI Na. General considerations on bioanalytical methods for comparative evaluation of biosimilars immunogenicity [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 721-728.
[7]	LU Chenyu, YANG Jun, LIU Yixi, ZHENG Yun. Function and regulation of miRNAs associated with Parkinson's disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 775-783.
[8]	LI Qingna, HUANG Ke, LU Fang, ZHAO Yang, QIU Panbo, WANG Shuge, GAO Rui. Characteristic and development of standard operating procedure of electronic data management in traditional Chinese medicine clinical research [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 550-554.
[9]	GUO Wei, XIE Linli, CAO Liya, XIE Jiangchuan, XIA Peiyuan, CHEN Yongchuan. Analysis of the current status of clinical drug trial institutions in Chongqing and reflections on the establishment of regional institutions [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(10): 1125-1130.
[10]	CHANG Qingqing, PENG Ying, WANG Guangji, SUN Jianguo. Clinical research progress of small molecule tyrosine kinase inhibitors as anti-hepatocellular carcinoma agents [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(8): 948-956.
[11]	GAO Yuanfeng, LI Shan, LIU Lin, OUYANG Rong. Research progress of abnormally expressed lncRNAs in glioma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(5): 586-591.
[12]	XIAO Liang, ZHENG Gaozhe, HUANG Yumin. Research progress on risk-based management in clinical trials [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(8): 955-960.
[13]	SHAN Jiao-jiao,TANG Yi-qun,SHI Mei-qi, XIA Guo-hao, WANG Li,FANG Ying,ZHAO Jie. Impact of clinical pharmacists on protocol deviation in anti-cancer drug clinical trial [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(1): 33-37.
[14]	LUO Zhi-ying, ZHANG Wei. The educational strategies for pharmacogenomics Translational Medicine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(5): 588-592.
[15]	WANG Hui, HU Si-yuan. Clinical research design technical points on child anorexia treated by new TCM drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(10): 1191-1195.